Trieu Vuong's Form 4 filing
Oncotelic Therapeutics, Inc. (OTLC) · filed Jun 24, 2026
- Accession no.
- 0001493152-26-029997
- Filed
- Jun 24, 2026, 8:37 PM ET
- Trade date
- Jun 22-24, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market purchases total $11.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Trieu VuongCIK 0001587074 | Director, Officer (CHAIRMAN AND CEO), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 24, 2026 | Common Stock | PPurchaseAcquired | +115,000 | $0.045 | +$5,175 | 93,884,319 | Direct | |
| Jun 23, 2026 | Common Stock | PPurchaseAcquired | +75,000 | $0.045 | +$3,375 | 93,769,319 | Direct | |
| Jun 22, 2026 | Common Stock | PPurchaseAcquired | +65,000 | $0.045 | +$2,925 | 93,694,319 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.